Form 4: ARTIVION CEO Mackin Reports Stock Unit Vesting, Tax Sale

ARTIVION, Inc. CEO James P. Mackin reported the vesting of performance stock units and a subsequent 'sell to cover' transaction for tax obligations.

Summary

• James P. Mackin, President & CEO of ARTIVION, INC. (AORT), reported changes in his beneficial ownership.
• On March 2, 2026, Mackin acquired 116,948 shares of common stock at a price of $0, representing the vesting of performance stock units.
• These units were part of a grant made on February 28, 2025, with this issuance being the first one-third portion.
• On March 3, 2026, Mackin sold 17,887 shares of common stock at $37.7756 per share.
• This sale was a "sell to cover" transaction, executed solely to satisfy tax withholding obligations related to the vested performance stock units and was not a discretionary transaction.
• Following these transactions, Mackin's beneficial ownership stands at 947,275 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. The vesting of performance units suggests performance targets were met, which is positive, but the subsequent tax-related sale is a routine, non-discretionary event that doesn't signal new strategic direction or sentiment.

Positives

• The vesting of 116,948 performance stock units indicates the achievement of performance criteria set by the company for its CEO.
• The "sell to cover" transaction is a standard practice for executives to manage tax liabilities on vested equity, not a discretionary sale indicating a lack of confidence.

Negatives

• A portion of shares (17,887) was sold, reducing the CEO's direct beneficial ownership, although this was for tax purposes.

Future Outlook

The remaining two-thirds of the performance stock units granted on February 28, 2025, are scheduled to vest in equal tranches on February 28, 2027, and February 28, 2028, contingent upon James P. Mackin's continued employment with ARTIVION, INC.

Industry Context

StockSavvy.ai notes that executive equity compensation, including performance stock units, is a common practice in the medical device and healthcare technology sectors to align management incentives with shareholder value. The 'sell to cover' transaction is a routine mechanism for executives to manage tax liabilities upon vesting, reflecting a standard operational aspect of executive compensation rather than a strategic move.

Comparison to Industry Standards

• This type of equity grant and subsequent tax-related sale is standard practice across publicly traded companies, particularly in the medical technology sector.
• For instance, similar 'sell to cover' transactions are frequently observed among executives at companies like Medtronic (MDT), Abbott Laboratories (ABT), and Boston Scientific (BSX) when their restricted stock units or performance shares vest.
• The vesting schedule over multiple years is also typical for long-term incentive plans designed to retain key executives and incentivize sustained performance.

Stakeholder Impact

• Shareholders: The vesting of performance units aligns executive incentives with shareholder value creation. The "sell to cover" transaction is a standard, non-discretionary event and does not reflect a change in management's confidence.
• Employees: The continued vesting schedule for the CEO's equity compensation may signal stability in executive leadership and the company's long-term incentive programs.

Next Steps

• The remaining two-thirds of the performance stock units granted on February 28, 2025, are eligible to vest on February 28, 2027, and February 28, 2028, subject to continued employment.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation events—the vesting of performance stock units and a subsequent 'sell to cover' transaction for tax purposes. These are expected occurrences and do not provide new fundamental information that would warrant a change in investment thesis. The transactions reflect standard executive compensation practices and do not indicate a discretionary buy or sell decision by the CEO based on new insights into the company's prospects. Therefore, a 'hold' recommendation is appropriate as this filing does not present a catalyst for significant price movement or a re-evaluation of the company's intrinsic value.

Keywords

ARTIVION, AORT, James P. Mackin, Form 4, Insider Trading, Stock Units, Performance Stock Units, Executive Compensation, Stock Vesting, Sell to Cover, Beneficial Ownership